Instant Report

Date: 19-Feb-2021

Chugai Refiles Patent Infringement Lawsuit Against Sawai Pharmaceu, Nichi-Iko & Nissan Chemical On Edirol Capsules

Chugai Pharmaceutical announced that it has refiled a patent infringement lawsuit with the Tokyo District Court, based on the substance patent owned by Chugai, regarding the generic drugs of an osteoporosis agent, active vitamin D3 derivative Edirol capsule 0.5 g / 0.75 g (generic name: eldecalcitol, hereafter, Edirol capsule) against Sawai Pharmaceu, Nichi-Iko Pharmaceutical (Nichi-Iko) and Nissan Chemical Corporation (Nissan Chemical) as per below. The lawsuit was initially filed on November 27, 2020, but the proceeding was withdrawn for litigation strategic reasons on January 15, 2021.

On February 17, 2020, Sawai and Nichi-Iko obtained approval from the Ministry of Health, Labour and Welfare for their generic drugs of Edirol capsule, respectively. At this point, only Sawai and Nichi-Iko have launched the generic drug. Nissan Chemical has recently been focusing on the API business of eldecalcitol for the generic drug of Edirol capsule.

In response to this situation, Chugai filed a patent infringement lawsuit with the Tokyo District Court, based on the substance patent owned by Chugai, demanding the suspension of production and use and disposal of the crystalline form, for which Chugai holds the patent, in association with the generic drug, and also demanding damage compensation against Sawai, Nichi-Iko and Nissan Chemical. Concurrently, Chugai filed the petition for provisional disposition order against the above three companies.

In this proceeding, Chugai recognizes that Sawai and Nichi-Iko have outsourced the manufacturing of the active pharmaceutical ingredient (API) to Nissan Chemical, purchased and used the API from Nissan Chemical to manufacture and sell their generic drugs, and at that time the above three companies have been producing and using the crystalline form for which Chugai holds the patent in order to manufacture and sell their generic drugs. Chugai alleges that said action infringes the substance patent (patent number 3429432) owned by Chugai.